The library · 17 briefs
Research breakdowns
Explore the targets, cellular responses and possibilities behind emerging research. RUO adaptations identify their members-only sources and distinguish experimental findings from human outcomes.
17 of 17 briefs
Thymosin Alpha-1 Before You Get Sick: Understanding Immune Readiness
What the Flu Vaccine Research Shows—and What It Hasn’t Proven
Read the brief
Evidence
Human influenza-vaccine antibody-response trial in older men; lab and animal immune mechanisms. Seasonal-flu prevention is unproven.
Research BasicsSemaglutide: longer signaling, a different experience of hunger
From GLP-1 receptor activation to appetite and glucose handling: why prolonged exposure matters, and why satiation, satiety and insulin are different parts of the story.
Read the brief
Evidence
Peptide design + controlled human appetite research
GLP-1 ResearchMetabolic HealthTirzepatide: two incretin signals, one coordinated response
GIP and GLP-1 help communicate the arrival of a meal. Tirzepatide brings both receptor targets into one peptide, linking appetite research with glucose-handling biology.
Read the brief
Evidence
Receptor pharmacology, animal work + early human research
GLP-1 ResearchMetabolic HealthRetatrutide: connecting appetite, glucose and fuel handling
GLP-1, GIP and glucagon receptor activity give retatrutide three connected biological branches. The opportunity is coordinated signaling—not a guarantee from counting targets.
Read the brief
Evidence
Structural and signaling studies + phase 2 human trial
GLP-1 ResearchMetabolic Health5-amino-1MQ: redirecting resources inside the fat cell
NNMT sits at a junction of nicotinamide and methyl-group metabolism. Inhibiting it offers a different research angle on adipose biology from suppressing appetite.
Read the brief
Evidence
Enzyme and cell experiments + mouse obesity model
Metabolic HealthATX-304 / O304: following the cell’s energy-sensing response
AMPK connects cellular energy status with fuel use. The O304 research program links this mechanism to glucose handling and perfusion, including a short human proof-of-concept study.
Read the brief
Evidence
Cell and mouse experiments + 28-day human proof of concept
Metabolic HealthRecovery & RepairSANA (MVD1): using creatine turnover to increase energy demand
A salicylate-derived small molecule explores creatine-dependent thermogenesis: increase ATP demand in adipose tissue, then study how fuel oxidation responds.
Read the brief
Evidence
Preclinical creatine-pathway work + early human safety/PK
Metabolic HealthMitochondriaSemax: neurotrophin signaling and the biology of adaptation
BDNF and TrkB connect cellular maintenance with plasticity. Semax research explores that signaling relationship, with preclinical findings kept distinct from human enhancement claims.
Read the brief
Evidence
Glial cell cultures + rat hippocampal signaling research
NootropicsSelank: exploring calm without equating it with sedation
GABA-associated modulation gives Selank a mechanistic research angle. Reducing anxiety-related interference is a different goal from broadly slowing neural activity.
Read the brief
Evidence
Rat gene-expression work + small active-comparator human study
NootropicsPeptide reactions: histamine, allergy and irritation are not the same
Mast-cell signaling can explain some itching and swelling, but similar-looking reactions can have different causes. Understanding the mechanism must not minimize systemic symptoms.
Read the brief
Evidence
Mast-cell experiments + authoritative allergy guidance
Research BasicsRecovery & RepairBPC-157, KPV and larazotide: three angles on the gut barrier
Mucosal repair research, inflammatory signaling and dynamic tight junctions address different biological problems. That makes the combination a research rationale, not a clinically proven blend.
Read the brief
Evidence
Separate preclinical mechanisms + a larazotide human trial
Gut HealthRecovery & RepairFLGR-242: a plausible follistatin design still needs compound data
Myostatin and activin biology explain the interest in follistatin-related designs. An albumin-binding proposal is not proof that the finished FLGR-242 compound performs as described.
Read the brief
Evidence
Foundational cell and animal biology; FLGR-242 performance unverified
Recovery & RepairKPV after surgery: inflammation has a timeline
Early inflammation helps initiate healing; persistent signaling can obstruct the transition to repair. KPV research raises a regulation question without proving selective protection of every healing response.
Read the brief
Evidence
KPV cell/mouse research + separate wound-healing biology
Recovery & RepairGut HealthSS-31: mitochondrial organization before metabolic promises
Cardiolipin helps organize the inner mitochondrial membrane. SS-31 research follows that interaction toward electron transport and energetic function, with weight-loss relevance still a hypothesis.
Read the brief
Evidence
Membrane and mitochondrial experiments; weight-loss application unproven
MitochondriaMetabolic HealthTablets and capsules: what binders and fillers actually do
Bulk, binding, disintegration and flow are formulation jobs—not automatic signs of poor quality. Uniform distribution and tested performance matter more than “filler-free” language.
Read the brief
Evidence
Formulation principles + FDA/USP quality standards
Research BasicsLarazotide: understanding the tight-junction research
Tight-junction biology meets a mixed human trial result. Why a proposed barrier mechanism is not proof of general gut repair.
Read the brief
Evidence
Human clinical research in persistent celiac symptoms
Gut HealthFrom mechanism to outcome: reading the evidence gap
Receptor binding, gene expression and a clinical endpoint answer different questions. A practical introduction to spotting where a research claim goes too far.
Read the brief
Evidence
Research-literacy primer · FDA guidance
Research Basics